Revision history
Back to the articleThese are preserved drafts. Earlier evidence may have changed; use the current reading to check availability.
Revision 1 · Continuing zoledronic acid reduced bone disease progression
Saved 2026-09-15 · Not clinically reviewed
Read this saved revision and its sources
In a follow-up subgroup of the Magnolia trial, patients whose myeloma had reached a very good partial response or better after 2 years of zoledronic acid were assigned to continued monthly treatment or observation. Continued treatment reduced progressive bone disease. The result concerns this responding subgroup and does not establish the same benefit for patients with weaker responses. This was a follow-up subgroup analysis limited to patients with very good partial response or better after 2 years, so it does not establish the same effect for patients with lesser responses. The hazard ratio's 95% confidence interval was 0.16-0.92, leaving uncertainty about the size of the effect.
In a follow-up subgroup of the Magnolia trial, patients whose myeloma had reached a very good partial response or better after 2 years of zoledronic acid were assigned to continued monthly treatment or observation. Continued treatment reduced progressive bone disease. The result concerns this responding subgroup and does not establish the same benefit for patients with weaker responses.
What the study found
In a follow-up subgroup of the Magnolia trial, patients whose myeloma had reached a very good partial response or better after 2 years of zoledronic acid were assigned to continued monthly treatment or observation. Continued treatment reduced progressive bone disease. The result concerns this responding subgroup and does not establish the same benefit for patients with weaker responses.
Continued zoledronic acid reduced the risk of progressive bone disease, with a hazard ratio of 0.40 and a 95% confidence interval of 0.16-0.92.
Who and what was studied
Patients who achieved a very good partial response or better after 2 years of zoledronic acid.
Continued monthly zoledronic acid beyond 2 years was compared with observation.
What remains uncertain
This was a follow-up subgroup analysis limited to patients with very good partial response or better after 2 years, so it does not establish the same effect for patients with lesser responses. The hazard ratio's 95% confidence interval was 0.16-0.92, leaving uncertainty about the size of the effect.
Which parts of this research are relevant to the questions I should discuss with my care team?